Sanofi-Aventis and Novozymes in antibiotic development deal
This article was originally published in Scrip
Sanofi-Aventis and Novozymes have struck a global licensing agreement to develop and market a potential new antibiotic. The two firms will develop plectasin NZ2114, a drug candidate developed by Novozymes for the treatment of severe infections, such as pneumonia, septicaemia and complicated skin and soft tissue infections. Dr Marc Cluzel, senior vice-president of R&D at Sanofi-Aventis, says that the candidate, from a novel class of antimicrobials, is potentially more active against resistant bacteria than currently available treatments. It is a variant of plectasin, a defensin-type peptide antibiotic, which is active against resistant and sensitive Gram-positive bacteria such as Staphylococci and Streptococci. The French company has an exclusive worldwide licence for the development, registration and commercialisation of the drug. Plectasin NZ2114 is the first drug candidate that Novozymes has outlicensed for further preclinical and clinical development, it says. Financial terms were not disclosed.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.